09-27-2019 - Amazon S3 · Last update: 20-06-2018 08:52:59am Term: FINAL_PROGRAMM_PDF_FOOTER_RIGHT 16:00 - 17:30 Innate immune system and anti-mitotic agents: Two fields getting together

Last update: 20-06-2018 08:52:59am Term: FINAL_PROGRAMM_PDF_FOOTER_RIGHT

09-27-201914:00 - 15:30 CNS complications and management in systemic cancer patients 1

Moderation: M. Preusser, Vienna, AT

14:00 - 14:25 Cerebral edema and steroids in the era of immunotherapy

, Zürich, CHP. Roth

14:25 - 14:50 Neurological complications of immunotherapy

, Vienna, ATM. Preusser

14:50 - 15:15 Vascular complications in brain tumor patients: etiology, management and prevention

, Lille, CEDEX/FRE. Le Rhun

14:00 - 15:30 Current markers in immunotherapy 1

Moderation: S. Turajlic, London, GB

14:00 - 14:25 The clonal evolution and its impact on immunotherapy

, London, GBS. Turajlic

14:25 - 14:50 The value of PD-L1 as a biomarker beyond lung cancers

, London, GBK. Harrington

14:50 - 15:15 Targeting the microenvironment

, USW. Fridman

14:00 - 15:30 Preclinical models and imaging to guide clinical therapy 1

Moderation: S. Quezada, London, London/GB

14:00 - 14:25 Imaging of the immune system

14:25 - 14:50 Mouse models to study cancer immunology

, London, London/GBS. Quezada

14:50 - 15:15 Ex-vivo and 3D models: From mice to men


14:00 - 15:30 Special clinical scenarios in management of advanced melanoma 1

Moderation: P. Lorigan, Manchester, GB

14:00 - 14:25 Checkpoint inhibitors in special populations

, North Sydney, AUA. Menzies

14:25 - 14:50 When can we stop immunotherapy in patients with clinical benefit?

, Essen, DED. Schadendorf

14:50 - 15:15 What is the current systemic approach in poor prognostic advanced melanomas?

, Manchester, GBP. Lorigan

14:15 - 15:15 Multidisciplinary management of germline and somatic gene alterations in patients with metastaticbreast cancer

1

Moderation: J. Balmana, Barcelona, ES

14:15 - 14:30 Complex management of germline BRCA associated breast cancer

, Jerusalem, ILS. Paluch-Shimon

14:30 - 14:45 Germline testing: Who should we test and for what?

14:45 - 15:00 DNA repair mutations beyond germline BRCA: Do they matter for patient management? (somatic vs.

germline testing)

, Barcelona, ESJ. Balmana

14:15 - 15:15 Practical use of liquid biopsy for advanced NSCLC 1

14:15 - 14:25 Presentation by expert

, Singapore, SGD.S.W. Tan

14:25 - 15:15 Discussion led by Chair

, Lyon, CEDEX/FRM. Perol

14:15 - 15:15 SCLC: Is it time for novel therapies? 1


, New York, USC. Rudin


, Manchester, GBF. Blackhall


16:00 - 17:30 Innate immune system and anti-mitotic agents: Two fields getting together 1

16:00 - 16:20 Neutrophils and metastasis

16:20 - 16:40 Microphages and cancer

16:40 - 17:00 Micronucleation and taxanes

17:00 - 17:05 Introduction

17:05 - 17:10 Conclusions and perspectives

17:10 - 17:30 Modelling chromothripsis

16:00 - 17:30 Frontline in mRCC: Ready to select treatment? 1

Moderation: C. Porta, Pavia, IT

16:00 - 16:25 How to select patients for immunotherapy doublet

, Pavia, ITC. Porta

16:25 - 16:50 Biomarker in RCC: Clinical perspective

, Boston, UST. Choueiri

16:50 - 17:15 How to select patients for immunotherapy + VEGF inhibition

, Villejuif, CEDEX/FRL. Albiges

16:00 - 17:30 The clinical utility of analysing circulating tumor DNA in patients with colorectal cancer (CRC) 1

Moderation: T. Yoshino, Kashiwa, Chiba/JP

16:00 - 16:25 Methodological principles and current technological advances

, Graz, ATM. Speicher

16:25 - 16:50 Ongoing pivotal trials using liquid biopsy

, Kashiwa, Chiba/JPT. Yoshino

16:50 - 17:15 Potential clinical utility of analysing circulating tumor DNA for CRC

, USC. Montagut


16:15 - 17:15 Combination and sequence in advanced melanoma 1


, Villejuif, FRC. Robert


, USB. Chmielowski

16:15 - 17:15 Partial breast radiation therapy: Which patients, when, and with what technique? 1


, Paris, FRP. Poortmans


, Cambridge, GBC. Coles

09-28-201908:30 - 10:00 Beyond initial radical treatment of patients with lung cancer 1


08:35 - 08:55 Role of imaging follow-up (include second cancers)

, Besançon, CEDEX/FRV. Westeel

08:55 - 09:15 Active management of patient’s comorbidities LH including cardiac toxicity

, Maastricht, NLA. Dingemans

09:15 - 09:35 Patient perspective/expectations

, Bern, CHR. Ihlen

09:35 - 09:55 Role of patient reported outcome in patients' follow-up

, Chapel Hill, NY/USE. Basch


, Brussels, BET. Berghmans


08:30 - 10:00 Next challenges for cancer immunotherapy 1

Moderation: A. Marabelle, Villejuif, FR

08:30 - 08:50 Cell therapies

, Epalinges, CHG. Coukos

08:50 - 09:10 Turning cold into hot tumours

, Villejuif, FRA. Marabelle


, Villejuif, FRA. Marabelle

09:10 - 09:30 Working on the microbiome


09:35 - 09:55 Immunotherapy for locally advanced cancer (Adjuvant and neoadjuvant?)

, Villejuif, CEDEX/FRB. Besse

08:30 - 10:00 Meeting the liquid biopsy family 1

Moderation: M. Ignatiadis, Brussels, BE

08:30 - 08:55 New frontiers: Spliced variants

, Rotterdam, NLM. Lolkema

08:55 - 09:20 The truly Pandora’s box: Exosomes

, Baltimore, USC. Rolfo

09:20 - 09:45 The famous ones: Circulating tumour cells (CTCs) and circulating free DNA (cfDNA)

, Brussels, BEM. Ignatiadis


08:45 - 09:45 A family with MEN1 syndrome 1

Moderation: M.E. Pavel, Erlangen, DE

08:45 - 09:00 Genetic counselling and screening

, Oxford, Oxfordshire/GBA. Grossman

09:00 - 09:15 The endocrinologist and oncologist perspective: How to manage a patient with multiple NETs

, Erlangen, DEM. Pavel

09:15 - 09:30 The surgical perspective: Who to operate on, when and to what extent

, London, GBA. Frilling

09:30 - 09:50 Presentation of index case and family history

, Oxford, Oxfordshire/GBA. Grossman

08:45 - 09:45 Challenges in advanced GIST: Are we approaching cure? 1


, Paris, CEDEX/FRS. Bonvalot


, Essen, DES. Bauer

08:45 - 09:45 Locally advanced rectal cancer: What is the best perioperative treatment in 2019? 1


, Barcelona, ESR. Salazar


, USC. Rödel

08:45 - 09:45 Tackling the treatment options in triple negative metastatic breast cancer 1


, Villejuif, FRS. Delaloge


, Chapel Hill, NC/USL. Carey


10:15 - 11:45 Biology and early diagnosis of blood malignancies 1

Moderation: L. Quintanilla Fend, US


10:20 - 10:40 Early diagnosis of secondary myeloid malignancies

, Rehovot, ILL. Shlush

10:40 - 11:00 Early lesions in haematological neoplasms

, USL. Quintanilla Fend

11:00 - 11:20 Early molecular and computational diagnostics by liquid biopsies

, USD. Rossi

11:20 - 11:40 Clonal evolution in lymphoma

, USJ. Fitzgibbon


, USL. Quintanilla Fend

10:15 - 11:45 Next immunotherapy strategies for lung cancer 1

Moderation: M.C. Garassino, Milan, IT

10:15 - 10:35 Bispecific agents and other checkpoint inhibitors

, Milan, ITM.C. Garassino

10:35 - 10:55 Personalised vaccines


11:00 - 11:20 Bridging the gut microbiome and immune response in lung cancer

11:20 - 11:40 Cell therapy in thoracic tumours

, USG. Dotti


, Milan, ITM.C. Garassino


10:15 - 11:45 Precision medicine in melanoma therapy 1

Moderation: P.A. Ascierto, Napoli, IT

10:15 - 10:35 Prediction of resistance to targeted therapies

, Amsterdam, NLC. Blank

10:35 - 10:55 Prediction of resistance to immunotherapy

, Los Angeles, CA/USA. Ribas

10:55 - 11:15 Prediction of toxicity of immunotherapy

, Villejuif, FRC. Robert


11:20 - 11:40 Who are the long-term responders to immunotherapy and targeted therapy?

, Napoli, ITP. Ascierto


, Napoli, ITP. Ascierto

10:15 - 11:45 Pushing forward with immunotherapy in upper GI cancers 1

Moderation: M. Moehler, Mainz, DE


, Mainz, DEM. Moehler

10:35 - 10:55 Overview of the current landscape of immunotherapy in upper GI cancers

, Mainz, DEM. Moehler


, Nagoya, Aichi/JPK. Muro

11:00 - 11:20 Combination strategies: Primary tumour location specific or agnostic

, Nagoya, Aichi/JPK. Muro

11:20 - 11:40 Tackling resistance mechanisms as a priority

, Dundee, Scotland/GBR. Petty

11:40 - 12:00 Precision immunotherapy: Biomarker and patient selection

, New York, NY/USY. Janjigian


10:30 - 11:30 WHO grade II and III gliomas: State of the art management 1

Moderation: A.S. Berghoff, Vienna, AT

10:30 - 10:45 Proton therapy for low grade gliomas

, Villejuif, FRF. Dhermain

10:45 - 11:00 Diagnostics and molecular pathology: IDHwt and other subgroups

, USF. Sahm

11:00 - 11:15 Survivorship and delayed effects

, Vienna, ATA.S. Berghoff

11:15 - 11:35 Presentation of case/condition

, Vienna, ATA.S. Berghoff

10:30 - 11:30 Biomarkers for patient selection for checkpoint inhibitors in HNSCC: Where do we stand? 1


, Chicago, IL/UST. Seiwert


, Athens, GRA. Psyrri

10:30 - 11:30 How to sequence treatment in platinum-sensitive relapsed ovarian cancer 1


, Napoli, ITS. Pignata


, Houston, TX/USR. Coleman

10:30 - 11:30 Metastasis, dormancy and late recurrence 1


, München, DEC. Klein



10:30 - 11:30 Radiopharmaceuticals to treat lethal prostate cancer 1


, Sutton, GBC. Parker


, Athens, Attiki/GRA. Bamias

12:00 - 12:45 HPV vaccination for everybody? 1

12:00 - 12:45 HPV vaccination for everybody?

, London, GBJ. Cuzick

15:00 - 16:30 Optimal delivery of immuno-oncology (IO) in advanced NSCLC 1

Moderation: S. Peters, Lausanne, CH

15:00 - 15:20 Biomarkers for IO: Can we and should we?

, Lausanne, CHS. Peters

15:20 - 15:40 Optimal combination for first-line NSCLC

, Grosshansdorf, DEM. Reck


15:45 - 16:05 Can we combine radiotherapy with IO?

16:05 - 16:25 Challenging IO after toxicity or resistance

, Villejuif, CEDEX/FRB. Besse


, Lausanne, CHS. Peters


15:00 - 16:30 Novel therapeutic strategies in ABC: Immunotherapy, Antibody Drug Conjugates (ADCs) and beyond 1

Moderation: G. Curigliano, Milan, IT

15:00 - 15:25 HER2 overexpressing breast cancer

, Melbourne, VIC/AUS. Loi

15:25 - 15:50 DNA Repair strategies: Beyond PARP inhibition

15:50 - 16:15 Triple negative breast cancer (TNBC)

, Milan, ITG. Curigliano

15:00 - 16:30 Treating endometrial cancer in the molecular age 1

Moderation: M.R. Mirza, Copenhagen, DK

15:00 - 15:25 Has molecular classification changed the surgical approach in endometrial cancer?

, Innsbruck, ATC. Marth

15:25 - 15:50 Endometrial cancer enters the immunotherapy era

, Copenhagen, DKM.R. Mirza

15:50 - 16:15 Has molecular classification changed the medical approach in endometrial cancer?

, Leiden, NLC. Creutzberg

15:15 - 16:15 Is randomisation of clinical trials still the gold standard? 1

15:15 - 15:30 Why we need randomization

, Athens, Attica/GRU. Dafni

15:30 - 15:45 How non-randomized studies can lead to registration

, Villejuif, CEDEX/FRC. Massard

15:45 - 16:00 The voice of the Regulator (EMA)

, London, GBF. Pignatti

16:00 - 16:05 Presentation of case/condition: Review of novel agents licensed for use in the 21st century


15:15 - 16:15 Managing the frail patients 1

15:15 - 15:30 Data from geriatricians and others on the positive outcomes after proper evaluation

, Zeist, HL/NLM. Hamaker

15:30 - 15:45 Prehabilitation: The impact in surgery and medical oncology

, USS. Rostoft

15:45 - 16:00 Defining tolerability of immuno-oncology in frail patients

, Manchester, GBF. Gomes

16:45 - 18:15 Treatment of the primary tumour in the metastatic setting 1

16:45 - 17:05 The radiation perspective: Bladder carcinoma model

, Birmingham, GBN. James

17:05 - 17:25 The medical oncologist perspective

, Milan, ITA. Necchi

17:25 - 17:45 Biological rationale for treating the primary tumour

, London, GBC. Swanton


17:50 - 18:10 The urologist perspective: The RCC model

, Amsterdam, NLA. Bex


16:45 - 18:15 The even rarer sarcomas: Treating the untreatable 1

16:45 - 17:05 Clinical trials for the ultra-rare cancers: The regulator’s perspective

17:05 - 17:25 The pathologist's point of view: Methodology to make a difference

, USH. Schildhaus

17:25 - 17:45 Offering treatment without evidence - and financial coverage

, Milan, ITS. Stacchiotti

17:45 - 18:05 "Rare sarcoma is pants”: Help and comfort through new media

18:05 - 18:10 Introduction: Why differentiation matters

16:45 - 18:15 Challenges in the management of luminal ER + MBC 1

Moderation: F. Cardoso, Lisbon, PT

16:45 - 17:10 Management options after progression on CDK 4/6 inhibitors

, Prato, PO/ITA. di Leo

17:10 - 17:35 Mutation directed therapy for ER + breast cancer

, Houston, USM. Ellis

17:35 - 18:00 Addressing optimal first line therapy options in luminal ABC (endocrine alone vs. endocrine + targeted vs.

chemotherapy) (endocrine alone vs. endocrine + targeted vs. chemotherapy)

, Lisbon, PTF. Cardoso


16:45 - 18:15 Pancreatic cancer: Where are we now and where are we going? 1

16:45 - 17:05 Locally advanced disease: Drugs alone or considered addition of radiotherapy

, Modena, ITS. Cascinu

17:05 - 17:25 Can we be more precise in peri-operative therapy?

, Villejuif, CEDEX/FRM. Ducreux

17:25 - 17:45 New targets on the horizon: Integrating genomics with tumour microenvironment

, New York, NY/USE. O'Reilly

17:45 - 18:05 Molecular profiling of pancreatic cancer in guiding tumour biology understanding and drug target

discovery

, Bearsden, GBA. Biankin

09-29-201908:30 - 10:00 DNA damage response modification as a therapeutic strategy in head and neck cancer 1

Moderation: I. Braña Garcia, Barcelona, ES

08:30 - 08:50 Clinical trials of ATR inhibition

, London, GBM. Dillon

08:50 - 09:10 Nucleic acid sensing as a driver of tumour immunogenicity

09:10 - 09:30 Synthetic lethal approaches to enhancing chemotherapy and radiotherapy

, Villejuif, FRE. Deutsch


09:35 - 09:55 Windows of opportunity studies and basket trials on DNA damage modifiers

, Barcelona, ESI. Braña Garcia


, Barcelona, ESI. Braña Garcia


08:30 - 10:00 Molecular tumour board: Where do we stand? What’s next? 1

08:30 - 08:50 Tissue and liquid biopsies with MTB for phase 1 trial selection: Experience in the TARGET trial

, Manchester, GBM. Krebs

08:50 - 09:10 Liquid biopsy for diagnostic and longitudinal tracking of metastatic patients

, USG. Siravegna

09:10 - 09:30 Building of a comprehensive clinical and molecular genomics database for patients with

treatment-refractory cancers enrolled in clinical trials

09:30 - 09:50 Personalized oncogenomics: Is a precision approach necessary for every cancer, or is there a

therapy-driven bottleneck?

, Vancouver, British Columbia/CAD. Huntsman

08:30 - 10:00 Stratified treatment in metastatic colorectal cancer 1

Moderation: C. Koehne, Oldenburg, DE

08:30 - 08:30 Immunotherapy: Microsatellite instability high (MSI-H), microsatellite instability low (MSI-L)

, Oldenburg, DEC. Koehne

08:30 - 08:50 New models for colon cancer in preclinical research

, Glasgow, GBO. Sansom

08:50 - 09:10 RAS, BRAF and HER2 status

, Milan, ITS. Siena


, Candiolo, (TO)/ITL. Trusolino

09:15 - 09:35 New molecular stratification

, Barcelona, ESR. Dienstmann


08:45 - 09:45 Toxicity profiling of immunotherapy of cancer 1

Moderation: J.B.A.G. Haanen, Amsterdam, NL


, Amsterdam, NLJ. Haanen



08:55 - 09:10 Managing patients with irAEs unresponsive to corticosteroids

, USC. Ribi

09:10 - 09:25 Life threatening immune toxicities

, Villejuif, CEDEX/FRS. Champiat

08:45 - 09:45 Early diagnosis of neuroendocrine tumours (NETs): Increasing awareness and optimising diagnosticwork up

1


, USC. Toumpanakis


, Uppsala, SEK. Oeberg

08:45 - 09:45 Specificity of upper tract urothelial carcinoma biology and management 1


, Madrid, ESJ. Puente


, Berlin, DEM. De Santis


10:15 - 11:45 Glioblastoma treatment: Where should the future lead? 1

Moderation: N. Andratschke, Zürich, CH

10:15 - 10:35 Improving by combining old agents?

, USU. Herrlinger

10:35 - 10:55 Cancer stem cells: Are they a valid therapeutic target?

, Luxembourg, LUS. Niclou



11:05 - 11:25 Antibody drug conjugates in neuro-oncology: A new road?

, Rotterdam, NLM. van den Bent

11:25 - 11:45 New developments in radiation oncology: Promise and limitations

, Zürich, CHN. Andratschke

10:15 - 11:45 Tackling the diversity of triple negative early breast cancer (TNBC) 1

Moderation: V. Dieras , R. Dent ; Rennes, CEDEX 5/FR, Singapore, SG1 2 1 2

10:15 - 10:30 Getting to grips with the biology of TNBC

, Berlin, DEC. Denkert

10:30 - 10:45 Should we incorporate immunotherapy in early breast cancer?

, Singapore, SGR. Dent

10:45 - 11:00 PARP inhibitors and DNA - damaging cytotoxic

, Rennes, CEDEX 5/FRV. Dieras

11:00 - 11:15 Future directions in TNBC early breast cancer trials

, Neu-Isenburg, DES. Loibl



11:30 - 11:45 Neoadjuvant vs adjuvant approaches in early TNBC

, Barcelona, ESJ. Cortes Castan


10:15 - 11:45 DNA repair: From basic science to the clinic and back 1

Moderation: T. Helleday, Stockholm, SE

10:15 - 10:40 Exploiting DNA-repair vulnerabilities in cancer therapy

, USS. Jackson

10:40 - 11:05 MTHFD2 as a target in leukemia

, Stockholm, SET. Helleday

11:05 - 11:30 DNA repair enzymes as anti-cancer drug targets

10:15 - 11:45 Genomic tumour boards towards delivering a better prostate cancer 1

Moderation: M. Rubin, New York, US/US


, Barcelona, ESJ. Mateo


10:20 - 10:40 How genomic data can result in the better delivery of prostate cancer care and research

, London, GBJ. de Bono

10:40 - 11:00 Homogenising genomic reports: What clinicians need to know

, New York, US/USM. Rubin

11:00 - 11:20 Setting up genomic tumour boards: What can be done and what needs to be done?

, Ann Arbor, USS. Tomlins

11:20 - 11:40 Managing incidental germline findings: Ethical and practical challenges

, Sutton, Surrey/GBR. Eeles


10:30 - 11:30 Defining optimal response in myeloma 1

Moderation: J. San Miguel, Salamanca, ES

10:30 - 10:45 Imaging

, London, GBS. Barrington

10:45 - 11:00 Haematology

, Salamanca, ESJ. San Miguel

11:00 - 11:15 Molecular biology

, Toulouse, FRH. Avet-Loiseau


, Salamanca, ESJ. San Miguel

10:30 - 11:30 Oligorecurrent and oligoprogressive NSCLC 1

10:30 - 10:45 The medical oncologist’s perspective

, London, GBM. O'Brien

10:45 - 11:00 The surgeon’s perspective

, Terrassa, Barcelona/ESR. Rami-Porta

11:00 - 11:15 The radiotherapist’s perspective

, Amsterdam, NLS. Senan


10:30 - 11:30 Radiation-associated sarcoma 1

Moderation: R.L. Haas, Amsterdam, NL

10:30 - 10:45 Our profession’s worst nightmare

, Amsterdam, NLR.L. Haas

10:45 - 11:00 Contemplating being a fisherman

11:00 - 11:15 The chameleon of chameleons: The good, the bad and the most challenging

, Boston, MA/USS. George


10:30 - 11:30 How to choose between single agent and combination immunotherapy 1


, Pamplona, ESI. Melero



10:30 - 11:30 Improving the outcomes from anal cancer treatment: Radiotherapy strategies and systemic therapies 1


, Munich, DED. Modest


, Leeds, GBD. Sebag-Montefiore


, Leeds, GBD. Sebag-Montefiore

12:00 - 12:45 Ras signalling and cancer 1

12:00 - 12:45 Ras signalling and cancer

, USD. Bar-Sagi


15:00 - 16:30 Recent advances in thyroid cancer 1

15:00 - 15:20 Targeted therapy in thyroid cancer (including anaplastic): Current standards and emerging novel

therapeutics

, Barcelona, ESJ. Capdevila

15:20 - 15:40 State of the art management of medullary thyroid cancer


15:45 - 16:05 Insights in the biology and pathological diagnosis of thyroid malignancies

16:05 - 16:25 Tumour growth rate as a driver to commence treatment with TKI in RA-refractory differentiated thyroid

carcinoma


15:00 - 16:30 Update on novel therapies in ovarian cancer 1

Moderation: J.A. Ledermann, London, London/GB

15:00 - 15:20 Do we already have biomarkers that may predict response and/or resistance to PARP inhibitors?

, Edinburgh, GBC. Gourley

15:20 - 15:40 Rationale for, and an orientation to, immunotherapy

, Lausanne, CHL. Kandalaft

15:40 - 16:00 Where do we stand with PARP inhibitors in ovarian cancer treatment in 2019

, London, London/GBJ. Ledermann


, Barcelona, ESA. Oaknin

16:05 - 16:25 Results of immunotherapy trials in ovarian cancer: Where do we stand in 2019?

, Madrid, ESA. González Martín


15:00 - 16:30 Where will future technologies take us in metastatic breast cancer? 1

Moderation: J.S. Reis-Filho , F. André ; New York, NY/US, Villejuif, FR1 2 1 2

15:00 - 15:20 The role of artificial intelligence (AI)

, Gif Sur Yvette, FRN. Paragios

15:20 - 15:40 Targeting novel pathways in breast cancer

, New York, NY/USJ. Reis-Filho



15:50 - 16:10 Where are we with liquid biopsies in breast cancer?

, London, GBN. Turner

16:10 - 16:30 Next generation sequencing trials in metastatic breast cancer (ARTEMIS, AURORA, TAPUR, etc..)

(ARTEMIS, AURORA, TAPUR, etc

, Villejuif, FRF. André

15:00 - 16:30 Immunotherapy in thoracic malignancies: What has been achieved in 2019? 1

Moderation: A. Curioni, Zurich, CH

15:00 - 15:25 Does radiotherapy still have a role in stage III NSCLC in the era of immunotherapy? The radiotherapist’s

view

, USK. Franks

15:25 - 15:50 Does surgery still have a role in stage III NSCLC in the era of immunotherapy? The surgeon’s view

, Nijmegen, NLA. Verhagen

15:50 - 16:15 Where is immunotherapy for small cell lung cancer and mesothelioma now?

, Zurich, CHA. Curioni


15:00 - 16:30 The past year in sarcoma: Impact on clinical practice 1

Moderation: R.L. Jones, London, WA/GB

15:00 - 15:25 Metastatic soft tissue sarcoma

, London, WA/GBR. Jones

15:25 - 15:50 Bone sarcoma

, London, GBJ. Whelan

15:50 - 16:15 Primary soft tissue sarcoma

, Milan, ITA. Gronchi

15:00 - 16:30 Treatment developments in viral-associated HN malignancies 1

Moderation: A.T.C. Chan, Shatin, HK

15:00 - 15:25 EBV monitoring in nasopharyngeal Carcinoma: Staging, prognosis, treatment adaptation

, Shatin, HKA. Chan

15:25 - 15:50 Treatment de-escalation in HPV-related oropharyngeal cancer: Where do we stand?

, Lausanne, CHC. Simon

15:50 - 16:15 HPV monitoring in HPV-related oropharyngeal cancer

, USS. Bhide

15:15 - 16:15 Overcoming symptom burden in upper GI cancer 1

15:15 - 16:45 Presentation of case/condition: Jaundice

, London, GBS. Pereira

16:45 - 18:15 Presentation of case/condition: Peritoneal carcinomatosis

, USP. Piso

18:15 - 19:45 Presentation of case/condition: Pain control

, Lausanne, CHA. Wagner

19:45 - 21:15 Presentation of case/condition: Dysphagia

, Villejuif, CEDEX/FRL. Antonin


15:15 - 16:15 Perioperative therapy in melanoma 1

15:15 - 15:30 Neoadjuvant treatment

, North Sydney, NSW/AUG. Long


15:35 - 15:50 The role of surgery

, Amsterdam, NLA. van Akkooi

15:50 - 16:05 Adjuvant therapy: How to wisely choose the treatment and for whom

, Villejuif, FRA. Eggermont

15:15 - 16:15 Personalized cancer vaccines: A mainstay for future cancer therapy? 1



, USI. Dikic

16:45 - 18:15 Management of body resources in patients with advanced cancer 1

Moderation: S. Kaasa, Oslo, NO

16:45 - 17:10 Determinants of malnutrition and sarcopenia

, Edmonton, CAV. Baracos

17:10 - 17:35 Issues the clinician faces in order to apply these guidelines

, Oslo, NOS. Kaasa

17:35 - 18:00 Applying ESMO and ESPEN Guidelines: Acting before cachexia hits

, Freiburg, DEJ. Arends


16:45 - 18:15 Progress in the management of non-melanoma skin cancers 1

Moderation: R. Dummer, Zurich, CH

16:45 - 17:10 Update on basal cell carcinoma

, Zurich, CHR. Dummer

17:10 - 17:35 Squamous cell carcinoma

, Kiel, Schleswig-Holstein/DEA. Hauschild

17:35 - 18:00 New therapies for Merkel cell carcinoma

, Essen, DEJ. Becker

17:00 - 18:00 Liquid biopsies, tumour dormancy and minimal residual disease detection 1

17:00 - 17:15 Technical validity

17:15 - 17:30 Monitoring minimal residual disease in colorectal cancer

17:30 - 17:45 Metastases, dormancy and later recurrences


09-30-2019


08:30 - 10:00 Survivor care in the times of innovative therapies 1

08:30 - 08:50 Rehabilitation decreases impact of cancer on patient and society

, USN. Barizien

08:50 - 09:10 Sexuality: Practical counselling

09:10 - 09:30 Fighting fatigue: Evidence and folkore

, Montreal, CAA. Vigano

09:30 - 09:50 Lessons from pediatric oncology

, USG. Armstrong


08:30 - 10:00 Targeting tumour metabolism to impact outcome from prostate cancers 1

Moderation: A. Alimonti , P.P. Pandolfi ; Bellinzona, CH, Boston, MA/US1 2 1 2


, Bellinzona, CHA. Alimonti

08:35 - 08:55 Polyamine metabolism in prostate cancer

, Derio, ESA. Carracedo Perez


09:00 - 09:20 Genetics of lipid metabolism in prostate cancer

, Boston, MA/USP.P. Pandolfi

09:20 - 09:40 Targeting immunometabolism for cancer therapy

09:40 - 10:00 Metabolic requirements of prostate cancer

, Bellinzona, CHA. Alimonti


08:30 - 10:00 Management of lymphomas in light of the updated WHO classification 1

Moderation: M. Trneny, Prague, 2/CZ

08:30 - 08:55 Aggressive B-cell lymphomas

, Prague, 2/CZM. Trneny

08:55 - 09:20 T-cell lymphomas

, Aarhus C, DKF. D'Amore

09:20 - 09:45 Indolent B-cell lymphomas

, London, GBS. Montoto

08:45 - 09:45 Treating young patients with BRCA-mutated early breast cancers 1

Moderation: O. Gentilini, US

08:45 - 09:00 Tailoring radiation treatment in patients with BRCA mutated tumours

, USB. Offersen

09:00 - 09:15 Preserving fertility in young women receiving adjuvant chemotherapy

, Boston, USA. Partridge


09:20 - 09:35 Caveats in surgical decision-making in patients with BRCA mutated tumours

, USO. Gentilini

08:45 - 09:45 Are big data, deep learning and AI methods changing cancer care and research? 1


, USB. Al-Lazikani


, Rotterdam, NLS. Sleijfer


, Rotterdam, NLS. Sleijfer


08:45 - 09:45 How do we personalize treatment in stage III NSCLC 1


, Winterthur, CHM. Pless


, Essen, DEW. Eberhardt

08:45 - 09:45 Is there a role for immunotherapy in gliomas? 1


, Zürich, CHM. Weller


, Rotterdam, NLM. van den Bent

10:15 - 11:45 Individualised dosing of commonly used anti-cancer agents 1

Moderation: E. Calvo , R.H. Mathijssen ; Madrid, ES, Rotterdam, NL1 2 1 2

10:15 - 10:30 Drug-food interactions

, Pisa, ITM. Del Re

10:30 - 10:45 Therapeutic drug monitoring (TDM) of tyrosine kinase inhibitors (TKIs)

, USM. Joerger

10:45 - 11:00 Drug-drug interactions: Focus on acid-suppressive agents

, Rotterdam, NLR. Mathijssen

11:00 - 11:15 Pharmacogenomics guided adaptive dosing of fluoropyrimidines

, Amsterdam, NLJ. Schellens

11:15 - 11:30 Optimising dosing of I-O agents

, Madrid, ESE. Calvo




10:15 - 11:45 Selecting and sequencing therapy in previously untreated urothelial cancer 1

Moderation: T.B. Powles, London, GB

10:15 - 10:35 Immune therapy in combination with targeted therapy

, Villejuif, FRY. Loriot

10:35 - 10:55 Biomarkers beyond PD-L1 expression to predict outcome to immune therapy

10:55 - 11:15 Immune therapy in combination with chemotherapy

, London, GBT. Powles



11:25 - 11:45 Single agent immune therapy and immune combinations

, Boston, MA/USJ. Bellmunt

10:15 - 11:45 Single cell cancer analysis 1

10:15 - 10:40 Single cell DNA sequencing and the clonal evolution of epithelial cancers

10:40 - 11:05 Technological advances in single cell technology to dissect molecular circuitry of cancer from primary to

metastasis (Perturb-Seq, DroNucseq)

11:05 - 11:30 Single cell RNA sequencing to decipher epithelial cancers and their microenvironments

, USJ. Marioni


10:30 - 11:30 Peritoneal metastases from colorectal cancer 1

Moderation: J. Taieb, Paris, FR

10:30 - 10:45 The surgical oncology perspective

, USB. Rau

10:45 - 11:00 The medical oncology perspective

, Paris, FRJ. Taieb


11:05 - 11:20 The pathology perspective

, Caen, CEDEX 5/FRF. Bibeau

10:30 - 11:30 Young patients with stage IB2 cervical cancer 1

10:30 - 10:45 The role of surgery: Is there a place for conservative treatment?

, Munich, DES. Mahner

10:45 - 11:00 The role of the medical treatment: Is there a place for neoadjuvant chemotherapy?

, USM. McCormack

11:00 - 11:15 The role of radiotherapy treatment: Can modern techniques reduce the burden of toxicity?

, Leiden, NLR. Nout


10:30 - 11:30 Drug interaction and the key role of kidney function in onco-haematology 1


, USB. Sprangers


, Paris, CEDEX 13/FRV. Launay-Vacher

12:00 - 12:45 Caloric restriction mimetics, autophagy and cancer 1

12:00 - 12:45 Caloric restriction mimetics, autophagy and cancer

, Paris, CEDEX/FRG. Kroemer


15:00 - 16:30 How to use the available results of precision medicine clinical trials 1

Moderation: E. Calvo, Madrid, ES


15:07 - 15:22 Other platform trials of precision medicine

, Paris, FRC. Le Tourneau

15:22 - 15:37 Umbrella trials

, Oxford, GBT. Maughan

15:37 - 15:52 Including biomarkers in clinical trials: Biostatistician view

, Villejuif, FRX. Paoletti

15:52 - 16:07 Basket trials

, Leuven, BEP. Schoeffski

16:07 - 16:22 Precision medicine: Counterpoint

, Madrid, ESE. Calvo

15:00 - 16:30 Tumour neoantigens 1

Moderation: A. Bardelli, Candiolo, (TO)/IT

15:00 - 15:20 Cancer genomes and neoantigens

, Los Angeles, CA/USA. Ribas

15:20 - 15:40 From tumour antigens to HLA peptides in melanoma

, Rehovot, MD/ILY. Samuels

15:40 - 16:00 Functional basis of neopeptides immune surveillance



16:10 - 16:30 MMR repair driven neoantigens

, Candiolo, (TO)/ITA. Bardelli


15:00 - 16:30 The next horizon in metastatic non-small cell targeted therapy 1

Moderation: D. Planchard , L. Paz-Ares ; Villejuif, FR, Madrid, ES1 2 1 2

15:00 - 15:20 The optimal sequence: Does overall survival matter?

, Shatin, HKT.S.K. Mok

15:20 - 15:40 How to manage co-occurrence of drivers

, Madrid, ESL. Paz-Ares

15:40 - 16:00 Uncommon targets: BRAF, MET and NTRK

, Villejuif, FRD. Planchard

16:00 - 16:20 Targeted KRAS mutation

, Boston, MA/USP. Jänne

15:15 - 16:30 Options and limitations in oligometastatic disease and metastatic colorectal cancer (mCRC) 1

15:15 - 15:30 The radiation oncology perspective

, USM. Hawkins

15:30 - 15:45 The surgical perspective

, USR. Raab

15:45 - 16:00 The medical oncology perspective

, Belfast, GBR. Wilson

16:00 - 16:15 The interventional radiology perpective

, Villejuif, FRT. de Baere

15:15 - 16:15 Treatment of pelvic node-positive prostate cancer 1

15:15 - 15:30 Systemic treatment: The role of chemotherapy and androgen receptor targeted therapy

, St. Gallen, CHS. Gillessen


15:35 - 15:50 Is there a role for radical surgery?

15:50 - 16:05 Advances in pelvic nodal radiotherapy

, USG. De Meerleer


15:15 - 16:15 Squamous cell carcinoma of the oesophagus 1

15:15 - 16:05 Presentation by Chair

, Odense C, DKP. Pfeiffer

16:05 - 16:15 Discussion led by expert

, UST. Crosby

15:15 - 16:15 The promise of cure: Chemotherapy free therapies in CLL 1



, USJ. Gribben

16:45 - 18:15 Bronchial neuroendocrine tumours 1

16:45 - 17:10 The genomic landscape

, London, GBC. Thirlwell

17:10 - 17:35 Challenges in pathological and molecular classifications

, Milan, ITM. MILIONE

17:35 - 18:00 Seeking the optimal treatment sequence in advanced disease

, Clayton, NSW/AUE. Segelov

16:45 - 18:15 How to handle comorbidities in the treatment decision of stages I to III NSCLC 1

16:45 - 17:10 Other significant comorbidities

, Brussels, BET. Berghmans

17:10 - 17:35 Cardiac risk assessment

, Leeds, GBA. Brunelli

17:35 - 18:00 Pulmonary risk assessment

, Amsterdam, NLP. Baas


16:45 - 18:15 Optimal adjuvant and neo-adjuvant therapy in HER-2 + patients 1

Moderation: A. Prat, Barcelona, ES

16:45 - 17:10 Optimal current regimens in the adjuvant setting

, Munich, DEN. Harbeck

17:10 - 17:35 Dissecting the heterogeneity of HER2+ breast cancer

, Barcelona, ESA. Prat

17:35 - 18:00 Lessons learned and opportunities from the neo-adjuvant setting

, Chapel Hill, NC/USL. Carey

17:00 - 18:00 Precision medicine for sarcoma: Are we there yet? 1

Moderation: E. De Alava, Sevilla, ES

17:00 - 17:15 Insights from basic research

, Paris, FRO. Delattre

17:15 - 17:30 Insights from oncology

, Zerifin, ILD. Katz

17:30 - 17:45 Insights from pathology

, Sevilla, ESE. De Alava


, Zerifin, ILD. Katz

17:00 - 18:00 Treatment of locally recurrent head and neck cancers 1


17:05 - 17:20 Improving patient selection for surgical candidates

, Birmingham, West Midlands/GBH. Mehanna

17:20 - 17:35 Molecular insights into treatment decisions

, USI. Tinhofer

17:35 - 17:50 Indications for re-irradation

, Villejuif, FRP. Blanchard

Documents

09-27-2019 - Amazon S3 · Last update: 20-06-2018 08:52:59am Term: FINAL_PROGRAMM_PDF_FOOTER_RIGHT 16:00 - 17:30 Innate immune system and anti-mitotic agents: Two fields getting together